Factor H facilitates the clearance of GBM bound iC3b by controlling C3 activation in fluid phase

Danielle Paixão-Cavalcante1, Steven Hanson, Marina Botto

  • 1Molecular Genetics and Rheumatology Section, Faculty of Medicine, Imperial College, Hammersmith Campus, Du Cane Road, London, W12 0NN, UK.

Insights

Factor H (CFH) deficiency causes dense deposit disease (DDD) due to uncontrolled complement activation. Administering CFH to deficient mice reduced C3 fragment deposition in kidneys by regulating plasma complement, suggesting plasma C3 inhibition as a therapy for DDD.

Area of Science:

  • Nephrology
  • Immunology
  • Complement System Biology

Background:

  • Dense deposit disease (DDD) is linked to dysregulated complement alternative pathway activation.
  • Factor H (CFH)-deficient mice develop glomerulonephritis with DDD features due to uncontrolled C3 deposition.

Purpose of the Study:

  • To investigate the role of CFH in preventing renal damage in a mouse model of DDD.
  • To determine if exogenous CFH administration can restore complement regulation and reduce kidney damage.

Main Methods:

  • Administered purified mouse CFH (mCFH) to CFH-deficient (Cfh(-/-)) mice.
  • Measured plasma C3 levels and deposition of C3 fragments (iC3b) along the glomerular basement membrane (GBM).
  • Analyzed glomerular C3 deposition and its origin via Western blot.

Main Results:

  • mCFH administration restored intact C3 in circulation, indicating control of fluid-phase C3 activation.
  • Reduced deposition of the C3 fragment iC3b along the GBM in treated mice.
  • Exogenous mCFH was detected in plasma but not bound to GBM, showing its effect was indirect.

Conclusions:

  • C3 deposition in the GBM of Cfh(-/-) mice consists of the iC3b fragment, originating from plasma C3 activation.
  • The therapeutic effect of mCFH relies on regulating plasma C3 activation, not direct GBM deposition.
  • Inhibiting C3 turnover in plasma is a promising therapeutic strategy for Dense Deposit Disease.

Related Concept Videos

Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Complement System01:27

Complement System

The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a membrane...
Coagulation01:09

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...